• In early July 2026, Agilent Technologies expanded its Altura HPLC column portfolio with new size exclusion chromatography (SEC) and PLRP-S columns, and introduced the AI-powered xCELLigence RTCA eSight AI module to streamline label-free imaging analysis in biopharmaceutical research.
• Together, these launches highlight Agilent’s focus on higher-value consumables and integrated AI-enabled workflows that aim to improve data quality, efficiency and reproducibility across complex biotherapeutic development.
• Next, we’ll examine how Agilent’s push into AI-enabled analysis and advanced biopharma columns could influence its broader investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Agilent Technologies Investment Narrative Recap

To own Agilent, you need to believe in steady demand for high quality lab tools, plus a shift toward higher margin consumables and software. The latest Altura columns and eSight AI module support that recurring revenue story, but do not materially change near term catalysts, which still center on execution of its FY2026 growth guidance and cost savings, while key risks include tariff driven margin pressure and possible weakness in academic and government funding.

Among recent updates, the OpenAI and Boston Consulting Group collaboration on AI across Agilent’s products ties in most directly with the new eSight AI launch, reinforcing the theme of more integrated, software rich workflows that could support recurring revenue growth and help offset risks around slower capital replacement cycles and rising supply chain complexity.

Yet investors should also recognize the risk that higher tariff driven costs and supply chain shifts could still weigh on margins if mitigation efforts lag...

Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029. This requires 6.7% yearly revenue growth and a roughly $0.7 billion earnings increase from $1.4 billion today.

Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community valuations cluster between US$150.54 and US$174.76 per share, showing how widely individual views can spread. Set against this, Agilent’s push into higher value consumables and AI enabled workflows could matter a lot for how its earnings power develops over time, so it is worth weighing several different opinions before deciding how this fits in your portfolio.

Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 31% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.